Seamus Kent
A5079231510- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Global Health Care Issues
- COVID-19 Clinical Research Studies
- Obesity and Health Practices
- Healthcare Policy and Management
- COVID-19 and healthcare impacts
- Lipoproteins and Cardiovascular Health
- Economic and Environmental Valuation
- Bariatric Surgery and Outcomes
- Total Knee Arthroplasty Outcomes
- Advanced Causal Inference Techniques
- Obesity, Physical Activity, Diet
- Orthopaedic implants and arthroplasty
- Healthcare cost, quality, practices
- Orthopedic Infections and Treatments
- Lung Cancer Research Studies
- Dialysis and Renal Disease Management
- Lung Cancer Treatments and Mutations
- Chronic Kidney Disease and Diabetes
- Blood Pressure and Hypertension Studies
- Biosimilars and Bioanalytical Methods
- Primary Care and Health Outcomes
- COVID-19 epidemiological studies
- Rheumatoid Arthritis Research and Therapies
Erasmus University Rotterdam
2024-2025
National Institute for Health and Care Excellence
2020-2023
University of Oxford
2013-2021
University of Leeds
2019
Leeds General Infirmary
2019
Nuffield Health
2017
University of Glasgow
2014-2016
Center for Assessment
2013
Finnish Institute for Health and Welfare
2013
New York University Press
2013
BackgroundLate-stage isolated medial knee osteoarthritis can be treated with total replacement (TKR) or partial (PKR). There is high variation in treatment choice and little robust evidence to guide selection. The Total Partial Knee Arthroplasty Trial (TOPKAT) therefore aims assess the clinical effectiveness cost-effectiveness of TKR versus PKR patients compartment knee, this represents an analysis main endpoints at 5 years.MethodsOur multicentre, pragmatic randomised controlled trial was...
Hydroxychloroquine, a drug commonly used in the treatment of rheumatoid arthritis, has received much negative publicity for adverse events associated with its authorisation emergency use to treat patients COVID-19 pneumonia. We studied safety hydroxychloroquine, alone and combination azithromycin, determine risk routine care arthritis.
ABSTRACT Background Hydroxychloroquine has recently received Emergency Use Authorization by the FDA and is currently prescribed in combination with azithromycin for COVID-19 pneumonia. We studied safety of hydroxychloroquine, alone azithromycin. Methods New user cohort studies were conducted including 16 severe adverse events (SAEs). Rheumatoid arthritis patients aged 18+ initiating hydroxychloroquine compared to those sulfasalazine followed up over 30 days. Self-controlled case series...
Abstract Comorbid conditions appear to be common among individuals hospitalised with coronavirus disease 2019 (COVID-19) but estimates of prevalence vary and little is known about the prior medication use patients. Here, we describe characteristics adults COVID-19 compare them influenza We include 34,128 (US: 8362, South Korea: 7341, Spain: 18,425) patients, summarising between 4811 11,643 unique aggregate characteristics. patients have been majority male in US Spain, predominantly female...
Reliable estimates of the impacts chronic kidney disease (CKD) stage, with and without cardiovascular disease, on hospital costs are needed to inform health policy.The Study Heart Renal Protection (SHARP) randomized trial prospectively collected information progression, serious adverse events care use in a cohort patients moderate-to-severe CKD. In secondary analysis SHARP data, impact participants' CKD non-fatal deaths annual (i.e. all admissions, routine dialysis treatments recorded...
There is growing interest in using observational data to assess the safety, effectiveness, and cost effectiveness of medical technologies, but operational, technical, methodological challenges limit its more widespread use. Common models federated networks offer a potential solution many these problems. The open-source Observational Medical Outcomes Partnerships (OMOP) common model standardises structure, format, terminologies otherwise disparate datasets, enabling execution analytical code...
Abstract Background In this study we phenotyped individuals hospitalised with coronavirus disease 2019 (COVID-19) in depth, summarising entire medical histories, including medications, as captured routinely collected data drawn from databases across three continents. We then compared COVID-19 to those previously influenza. Methods report demographics, recorded conditions and medication use of patients the US (Columbia University Irving Medical Center [CUIMC], Premier Healthcare Database...
Background Late-stage medial compartment knee osteoarthritis can be treated using total replacement or partial (unicompartmental) replacement. There is high variation in treatment choice and insufficient evidence to guide selection. Objective To assess the clinical effectiveness cost-effectiveness of compared with patients osteoarthritis. The findings are intended surgical decision-making for patients, surgeons health-care providers. Design This was a randomised, multicentre, pragmatic...
Transparency in health economic decision modelling is important for engendering confidence the models and reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead promoting transparency through validation with biennial conferences which diabetes groups meet to compare simulated outcomes pre-specified scenarios often based on results pivotal clinical trials. Model registration potential method transparency, while also reducing...
[Figure: see text].
Excess weight is associated with poor health and increased health-care costs. However, a detailed understanding of the effects excess on total hospital costs for different conditions needed.
Health technology assessment (HTA) is increasingly informed by nonrandomized studies, but there limited guidance from HTA bodies on expectations around evidence quality and study conduct. We developed recommendations to support the appropriate use of such based a pragmatic literature review workshop involving 16 experts eight countries as part EU's Horizon-2020 IMPACT-HTA program (work package six). To ensure processes remain rigorous robust, should demand clear, extensive structured...
<h3>Objectives</h3> A policy model is a that can evaluate the effectiveness and cost-effectiveness of interventions inform decisions. In this study, we introduce cardiovascular disease (CVD) which be used to remaining life expectancy including measure socioeconomic deprivation as an independent risk factor for CVD. <h3>Design</h3> state transition was developed using Scottish Heart Health Extended Cohort (SHHEC) linked morbidity death records. Individuals start in CVD-free transit three CVD...
<h3>Objective</h3> To present a long-term policy model of cardiovascular disease (CVD) in moderate-to-advanced chronic kidney (CKD). <h3>Methods</h3> A Markov with transitions between CKD stages (3B, 4, 5, on dialysis, transplant) and events (major atherosclerotic events, haemorrhagic stroke, vascular death) was developed individualised CVD risks estimated using the 5 years' follow-up data 9270 patients moderate-to-severe Study Heart Renal Protection (SHARP) multivariate parametric survival...
Objective. To compare a range of statistical models to enable the estimation EQ-5D-3L utilities from responses Parkinson’s Disease Questionnaire 39 (PDQ-39). Methods. Linear regression, beta mixtures linear regressions and regressions, multinomial logistic regression were compared in terms their ability accurately predict PDQ-39 using mean error (ME), absolute (MAE), square (MSE), overall by Hoehn Yahr stage. Models estimated data PD MED trial ( n = 9123) assessed on both as well external...
Simvastatin, 20mg, plus ezetimibe, 10mg, daily (simvastatin ezetimibe) reduced major atherosclerotic events in patients with moderate to severe chronic kidney disease (CKD) the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown.Cost-effectiveness simvastatin ezetimibe SHARP, a randomized controlled trial.9,270 CKD randomly assigned versus placebo; participants categories by 5-year cardiovascular risk (low, <10%; medium, 10%-<20%; or high, ≥20%) stage (3, 4, 5...
Objective The study objective was to estimate the cost‐effectiveness of a commercially provided low‐energy total diet replacement (TDR) program compared with nurse‐led behavioral support. Methods A multistate life table model and weight reduction observed in randomized controlled trial were used evaluate quality‐adjusted life‐years direct health care costs (in United Kingdom 2017 prices) over lifetime TDR versus support adults who had obesity, assuming that (i) returns baseline 5 years (ii)...
Over 100,000 primary knee arthroplasty operations are undertaken annually in the UK. Around 15-30% of patients do not report a good outcome. Better rehabilitation strategies may improve patient-reported outcomes.To compare outcomes from traditional outpatient physiotherapy model with those home-based programme for people assessed as being at risk poor outcome after arthroplasty.An individually randomised, two-arm controlled trial blinded assessment, parallel health economic evaluation and...
Objective To compare real-world effectiveness and safety of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (AFib) for prevention stroke. Study design setting A comparative cohort study UK general practice data from The Health Improvement Network database. Participants interventions Before matching, 5655 ≥18 years AFib who initiated at least one DOAC between 1 July 2014 31 December 2020 were included. DOACs interest included apixaban, rivaroxaban, edoxaban...
Objectives: The use of value information methods to inform trial design has been widely advocated but there have few empirical applications these and is little evidence they are used in decision making. This study considers the usefulness models context a real clinical problem relating alternative diagnostic strategies for patients with recent non-ST elevated myocardial infarction. Methods: A pretrial economic model constructed consider cost-effectiveness two competing strategies: coronary...